RxDoctor Payments Data

Natasha Baron, MD

Child & Adolescent Psychiatry · Paramus, NJNPI 1104026186

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Viiv Healthcare Company at 37.4% of the total.

$387in general payments, 2019–2025

Across 14 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$145
  • Gilead$125
  • Alkermes, Inc.$38
  • Sunovion Pharmaceuticals Inc.$32
  • AbbVie$17
  • Bioxcel Therapeutics, Inc.$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$387100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$387 in reported general payments places this provider in the 65th percentile of 137 child & adolescent psychiatry providers in New Jersey.

See all child & adolescent psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$53,137
Medicare patients
124
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Divalproex Sodium26$1,273
Duloxetine Hcl14$742
Metoprolol Succinate14$454
Venlafaxine Hcl ErVenlafaxine Hcl17$283
Quetiapine Fumarate23$262
Clonazepam13$163
Sertraline Hcl15$155
Olanzapine13$109
Escitalopram Oxalate13$93

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →